Consequences of inflammatory arthritis for workplace productivity loss and sick leave: a systematic review
Authors:
- 1 April 2013
- journal article
- review article
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 72 (4) , 493-505
Abstract
Objective To review the occurrence and magnitude of workplace productivity loss and sick leave in inflammatory arthritis (IA) patients and to identify determinants. Methods PubMed, EMbase, PsycINFO and CINAHL articles to July 2012 on IA and workplace productivity loss or sick leave were reviewed. Methodological quality was assessed by a criteria list developed by the authors. Results 47 original studies were identified. The occurrence of sick leave in IA patients varied from 3.7% in the past 4 days to 84% in the past 2.5 years. Total duration of sick leave ranged from 0.1 to 11 days over 1 month. Pain and functional disability were associated with sick leave and workplace productivity loss. About 17%–88% of IA patients experienced workplace productivity loss, four studies investigated determinants. Tumour necrosis factor inhibitors were associated with reduced workplace productivity loss and sick leave. Conclusions IA impacts worker productivity, but its estimated magnitude varies. Higher levels of sick leave and workplace productivity loss were reported for increased levels of pain and decreased levels of functional ability.Keywords
This publication has 54 references indexed in Scilit:
- Improvement in work place and household productivity for patients with early rheumatoid arthritis treated with adalimumab plus methotrexate: Work outcomes and their correlations with clinical and radiographic measures from a randomized controlled trial companion studyArthritis Care & Research, 2010
- Productivity loss in the workforce: associations with health, work demands, and individual characteristicsAmerican Journal of Industrial Medicine, 2008
- Work and sick leave among patients with early inflammatory joint conditionsArthritis & Rheumatism, 2008
- The need for standardization: A literature review of indirect costs of rheumatoid arthritis and osteoarthritisArthritis Care & Research, 2008
- Infliximab treatment maintains employability in patients with early rheumatoid arthritisArthritis & Rheumatism, 2006
- Early suppression of disease activity is essential for maintenance of work capacity in patients with recent‐onset rheumatoid arthritis: Five‐year experience from the FIN‐RACo trialArthritis & Rheumatism, 2005
- High work disability rate among rheumatoid arthritis patients in LithuaniaArthritis Care & Research, 2004
- Impact of initial aggressive drug treatment with a combination of disease‐modifying antirheumatic drugs on the development of work disability in early rheumatoid arthritis: A five‐year randomized followup trialArthritis & Rheumatism, 2004
- Indirect medical costs in early rheumatoid arthritis: Composition of and changes in indirect costs within the first three years of diseaseArthritis & Rheumatism, 2001
- Function and health-related quality of life: Results from a randomized controlled trial of leflunomide versus methotrexate or placebo in patients with active rheumatoid arthritisArthritis & Rheumatism, 1999